© BusinessWire
15.12.2025
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
News Preview
The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of MLTX du...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
BAX
LISTED
NYSE
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
I...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
AB
LISTED
EURONEXT
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
News Preview
PRESS RELEASE...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© EQS Newswire
15.12.2025
991
LISTED
XETRA
successfull capital increase and strengthening of the financial structure
News Preview
Ad hoc announcement
Vitruvia Medical AG
December 15, 2025
Vitruvia Medical AG successfully completes capital increase and strengthens its financial structure
Vitruvia Medical AG announces that a capital increase was successfully completed on December 15, 2025. The newly created capital was used in full to repay the convertible bond due at th......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
15.12.2025
991
LISTED
XETRA
erfolgreiche Kapitalerhöhung und Stärkung der Finanzstruktur
News Preview
Ad-hoc-MitteilungVitruvia Medical AG15. Dezember 2025
Vitruvia Medical AG schliesst erfolgreiche Kapitalerhöhung ab und stärkt ihre Finanzstruktur
Die Vitruvia Medical AG gibt bekannt, dass am 15. Dezember 2025 erfolgreich eine Kapitalerhöhung durchgeführt wurde. Das neu geschaffene Kapital wurde vollständig zur Rückzahlung der Anfang Dezember f......
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
IPN
LISTED
EURONEXT
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
News Preview
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies....
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
TMO
LISTED
NYSE
OlivePoint Capital Acquires 3900 Paramount Parkway in Raleigh–Durham, Expanding Its High-Conviction Office Special Situations Strategy
News Preview
OlivePoint Capital (“OlivePoint”), an institutional real estate investment manager focused on thematic and special situations strategies, and Redwood Capital Management, LLC, a global alternative investment manager focused on opportunistic credit and other special situation investments (“Redwood Capital”), today announced its acquisition of 3900 P...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
BAX
LISTED
NYSE
Baxter International Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – BAX
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of BAX during the...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
BAX
LISTED
NYSE
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This p...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
MLTX
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. (“MoonLake” or the “Company”) (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
CON
LISTED
NASDAQ
Concentra Adds New Medical Center in Hialeah, Florida
News Preview
Concentra® (NYSE: CON), the nation’s leader in occupational medicine, today announced the opening of a new medical center in Hialeah, Florida. The medical center, Concentra Hialeah, is conveniently located at 855 East 8th Avenue, Hialeah, Florida 33010.
“Hialeah has shown great potential for Concentra,” said Janet Cobb, MD, senior vice president...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
15.12.2025
ITGR
LISTED
NYSE
ITGR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Integer Holdings Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that purchasers of Integer Holdings Corporation (NYSE: ITGR) common stock between July 25, 2024 and October 22, 2025, both dates inclusive (the “Class Period”), have until February 9, 2026 to seek appointment as lead plaintiff of the Integer Holdings class action lawsuit. Captioned West Palm Beach Fir...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
FEED
LISTED
NASDAQ
ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman
News Preview
ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team.
David Johnson, newly appointed Chairman of ENv...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
HUM
LISTED
NYSE
CenterWell Partners with Thyme Care for Comprehensive Cancer Care Support
News Preview
Senior-focused primary care providers CenterWell Senior Primary Care® and Conviva Senior Primary Care® are now partnering with Thyme Care to provide comprehensive cancer care support for eligible patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215558436/en/
Through Thyme Car...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
MLTX
LISTED
NASDAQ
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commiss...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
GILD
LISTED
NASDAQ
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
WGS
LISTED
NASDAQ
JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns) study has been recognized as part of JAMA’s annual Research of the Year Roundup. This highly selective honor is reserved for the most impactful scientific...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
CCRN
LISTED
NASDAQ
Cross Country Healthcare Announces CEO Transition
News Preview
Cross Country Healthcare, Inc. (the “Company” and “Cross Country”) (Nasdaq: CCRN) today announced that John A. Martins, the Company’s President and Chief Executive Officer, has separated from the Company and ceased to serve as a member of its Board of Directors (the “Board”), effective as of December 14, 2025. The Board appointed Kevin C. Clark, t...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
SLN
LISTED
NASDAQ
Silence Therapeutics Announces Leadership Changes
News Preview
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company’s President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Comp...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Reports Updated Clinical Results
News Preview
Expanded Clinical Experience Demonstrates Additional Long-Term Survival and Radiographic Remission in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 Expanded Clinical Experience Demonstrates Additional Long-Term Survival and Radiographic Remission in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranas...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
6446
LISTED
TAI
PharmaEssentia Announces Presentation at J.P. Morgan Healthcare Conference and Strategic Priorities for 2026
News Preview
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today outlined key accomplishments from 2025 and provided an overview of strategic priorities and anticipated m...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
SPRB
LISTED
OTC
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
News Preview
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Keli Walbert to the Company's Board of Directors.
“Keli joins the Board of Directors at a pivotal time as we pr...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ORY
LISTED
BME
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
News Preview
MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
SIA
LISTED
TSX
Sienna Announces December Dividend
News Preview
MARKHAM, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of December 2025, representing $0.936 per Common Share on an annualized basis....
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
ZTS
LISTED
NYSE
Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering
News Preview
Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
NEO
LISTED
NASDAQ
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
News Preview
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court’s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics’ fa...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
CPRX
LISTED
NASDAQ
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, Presiden...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
XRAY
LISTED
NASDAQ
Dentsply Sirona Declares Quarterly Cash Dividend
News Preview
CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
FBLG
LISTED
NASDAQ
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
News Preview
HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
VOR
LISTED
NASDAQ
Vor Bio Announces $150 Million Private Placement
News Preview
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accr...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
MBX
LISTED
NASDAQ
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
News Preview
CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will presen...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
BCAX
LISTED
NASDAQ
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
News Preview
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
IMNM
LISTED
NASDAQ
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoi...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
PODD
LISTED
NASDAQ
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future
News Preview
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers.
“Here at Insulet, our mission is to transform the lives of people with diabetes, and...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
CGC
LISTED
NASDAQ
Canopy Growth to Acquire MTL Cannabis; Transaction Expected to Create Canada’s Leading Medical Cannabis Business and Enhance Capacity to Serve Growing International Demand
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and MTL Cannabis Corp. (“MTL Cannabis” or “MTL”) (CSE: MTLC) (OTCQX: MTLNF) are pleased to announce that they have entered into a definitive arrangement agreement (the “Arrangement Agreement”) pursuant to which Canopy Growth will acquire all of the issued and ou...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
COR
LISTED
NYSE
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology
News Preview
Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset managem...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ABEO
LISTED
NASDAQ
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
News Preview
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company’s corporate strategy and business development functions, as well as drive operating efficienc...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS15 December 2025 at 14.30 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
News Preview
THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
RVV
LISTED
CSE
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
News Preview
TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluatin...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ZBIO
LISTED
NASDAQ
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
News Preview
- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE -...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
JBIO
LISTED
NASDAQ
Jade Biosciences Announces $45 Million Private Placement
News Preview
SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech fo...
Themefolio
Profiler
Peergroup
© Newsfile
15.12.2025
HBFG
LISTED
CSE
Happy Belly Food Group's Via Cibo Italian Fast-Casual Restaurant Signs a 10 Unit Development Agreement in Alberta
News Preview
Toronto, Ontario--(Newsfile Corp. - December 15, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands, is pleased to announce that it has signed an area development agreement for the province of Alberta for the contractual opening of ten (10) franchis...
Themefolio
Profiler
Peergroup
© Newsfile
15.12.2025
OSTX
LISTED
XASE
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
News Preview
FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated Approval Program pathway, as stated in FDA guidance documentsFDA proposed confirmatory study design include additional osteosarcoma disease settings suc...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
News Preview
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
PVLA
LISTED
NASDAQ
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
News Preview
73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants) rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Overall cVM-IGA at Week 12...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.12.2025
MDCE
LISTED
OTC
Medical Care Technologies, Inc. (OTC Pink:MDCE) Completes First AI Consumer App Targeting Deployment Across 100+ Countries and 30 Languages
News Preview
Company to Launch AI Food & Recipe App to Access Trillion-Dollar Global Food Market While Advancing Medical AI Pipeline MESA, ARIZONA / ACCESS Newswire / December 15, 2025 / Medical Care Technologies, Inc. (OTC Pink:MDCE) today announced the completion of its first AI-based consumer application, marking a major milestone in the Company's strate...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.12.2025
IGC
LISTED
XASE
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
News Preview
POTOMAC, MARYLAND / ACCESS Newswire / December 15, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today commented on recent federal policy momentum surrounding the potent...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.12.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
News Preview
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited approval pathway SAN FRANCISCO, CA / ACCESS Newswire / December 15, 2025 / Jaguar Health, Inc....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.12.2025
AYTU
LISTED
NASDAQ
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
News Preview
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain co...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
PLTR
LISTED
NASDAQ
Palantir Announces Renewal of Multi-Year Contract with the DGSI
News Preview
Palantir Technologies Inc. (NASDAQ: PLTR) announces a three-year renewal of its contract with the DGSI, France's domestic intelligence agency, extending a partnership that has been ongoing for nearly a decade. This agreement relates to the supply of Palantir’s proprietary software platform, as well as the integration, support, and assistance servi...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.12.2025
HBMN
LISTED
SIX
HBM Healthcare Investments gibt Vereinbarung zum Verkauf einer Mehrheitsbeteiligung an Swixx Biopharma bekannt
News Preview
Die auf den Gesundheitssektor spezialisierte Beteiligungsgesellschaft HBM Healthcare Investments hat die Unterzeichnung einer verbindlichen Vereinbarung zum Verkauf einer Mehrheitsbeteiligung an Swixx Biopharma bekannt gegeben. Im Rahmen der Transaktion wird HBM Healthcare Investments, zusammen mit den Gründern und anderen Aktionären wie Mérieux Eq......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.12.2025
HBMN
LISTED
SIX
HBM Healthcare Investments Announces Agreement to Sell Majority of Investment in Swixx Biopharma
News Preview
HBM Healthcare Investments, an investment company focused on the healthcare sector, has announced the signing of a binding agreement to sell a majority stake in Swixx Biopharma. As part of the transaction, HBM Healthcare Investments, together with the founders and other shareholders such as Mérieux Equity Partners, will sell a majority of their cur......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.12.2025
RLF
LISTED
SIX
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
News Preview
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
GENEVA (Dec. 15, 2025) – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, prec......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.12.2025
MRNA
LISTED
NASDAQ
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
News Preview
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the European Union, subject to authorization by the European Commission CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA)...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
SAN
LISTED
EURONEXT
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
News Preview
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.12.2025
AMPH
LISTED
NASDAQ
Amphastar Announces FDA Approval for Teriparatide Injection
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
SAN
LISTED
EURONEXT
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
News Preview
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
